MedTrace Logo

Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTP

NCT04985318 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2026-04-30

No results posted yet for this study

Summary

The objective of this national, prospective, multi-centre observational study is to describe the prescription rational and practice in Germany, confirm the efficacy of caplacizumab in a real-world setting, and identify predicting factors in iTTP-patients with regard to persistent autoimmune activity, therapy guidance and risk of complications. The rational is to develop new treatment algorithms that optimize overall patient outcome and reduce treatment cost.

Conditions

  • Acquired Thrombotic Thrombocytopenic Purpura

Interventions

DRUG

Cablivi®

Intervention with Cablivi® take place outside of the study

Sponsors & Collaborators

  • University of Cologne

    lead OTHER

Principal Investigators

  • Linus Völker, MD · Department II of Internal Medicine, University of Cologne

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-25
Primary Completion
2034-12-12
Completion
2034-12-12

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04985318 on ClinicalTrials.gov